Efficacy and safety of adjunctive corticosteroids therapy for severe community-acquired pneumonia in adults: An updated systematic review and meta-analysis

PLoS ONE

Volumn 11, Issue 11, 2016, Pages

  Bi, Jirui ^a   Yang, Jin ^a   Wang, Ying ^a   Yao, Cijiang ^a   Mei, Jing ^a   Liu, Ying ^a   Cao, Jiyu ^a   Lu, Youjin ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; HYDROCORTISONE; METHYLPREDNISOLONE; PREDNISOLONE;

ADJUVANT THERAPY; ADULT RESPIRATORY DISTRESS SYNDROME; ARTICLE; ARTIFICIAL VENTILATION; COMMUNITY ACQUIRED PNEUMONIA; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; GASTROINTESTINAL HEMORRHAGE; HOSPITAL PATIENT; HUMAN; HYPERGLYCEMIA; LENGTH OF STAY; META ANALYSIS; MORTALITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; SYSTEMIC THERAPY; TREATMENT DURATION; ADULT; COMMUNITY-ACQUIRED INFECTIONS; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PNEUMONIA; RESPIRATORY DISTRESS SYNDROME, ADULT;

ADRENAL CORTEX HORMONES; ADULT; COMBINED MODALITY THERAPY; COMMUNITY-ACQUIRED INFECTIONS; HUMANS; LENGTH OF STAY; PNEUMONIA; RESPIRATION, ARTIFICIAL; RESPIRATORY DISTRESS SYNDROME, ADULT;

EID: 84995387858     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0165942     Document Type: Article

References (55)

1. Woodhead M, Welch CA, Harrison DA, Bellingan G, Ayres JG. Community-acquired pneumonia on the intensive care unit: secondary analysis of 17,869 cases in the ICNARC Case Mix Programme Database. Crit Care. 2006; 10 Suppl 2:S1.
2. Said MA, Johnson HL, Nonyane BA, Deloria-Knoll M, O'Brien KL, Andreo F, et al. Estimating the burden of pneumococcal pneumonia among adults: a systematic review and meta-analysis of diagnostic techniques. PLoS One. 2013; 8(4):e60273. doi: 10.1371/journal.pone.0060273 PMID: 23565216
3. Wunderink RG, Waterer GW. Clinical practice. Community-acquired pneumonia. N Engl J Med. 2014; 370(6):543-51. doi: 10.1056/NEJMcp1214869 PMID: 24499212
4. Alvarez-Lerma F, Torres A. Severe community-acquired pneumonia. Curr Opin Crit Care. 2004; 10 (5):369-74. PMID: 15385753
5. Rodriguez A, Mendia A, Sirvent JM, Barcenilla F, de la Torre-Prados MV, Sole-Violan J, et al. Combination antibiotic therapy improves survival in patients with community-acquired pneumonia and shock. Crit Care Med. 2007; 35(6):1493-8. doi: 10.1097/01.CCM.0000266755.75844.05 PMID: 17452932
6. Mandell LA. Community-acquired pneumonia: An overview. Postgraduate medicine. 2015; 127(6):607-15. doi: 10.1080/00325481.2015.1074030 PMID: 26224210
7. Endeman H, Meijvis SC, Rijkers GT, van Velzen-Blad H, van Moorsel CH, Grutters JC, et al. Systemic cytokine response in patients with community-acquired pneumonia. The European respiratory journal. 2011; 37(6):1431-8. doi: 10.1183/09031936.00074410 PMID: 20884746
8. Martinez R, Menendez R, Reyes S, Polverino E, Cilloniz C, Martinez A, et al. Factors associated with inflammatory cytokine patterns in community-acquired pneumonia. The European respiratory journal. 2011; 37(2):393-9. doi: 10.1183/09031936.00040710 PMID: 20595152
9. Aliberti S, Brambilla AM, Chalmers JD, Cilloniz C, Ramirez J, Bignamini A, et al. Phenotyping community-acquired pneumonia according to the presence of acute respiratory failure and severe sepsis. Respiratory research. 2014; 15:27. doi: 10.1186/1465-9921-15-27 PMID: 24593040
10. Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids?new mechanisms for old drugs. N Engl J Med. 2005; 353(16):1711-23. doi: 10.1056/NEJMra050541 PMID: 16236742
11. Marik PE, Pastores SM, Annane D, Meduri GU, Sprung CL, Arlt W, et al. Recommendations for the diagnosis and management of corticosteroid insufficiency in critically ill adult patients: consensus statements from an international task force by the American College of Critical Care Medicine. Crit Care Med. 2008; 36(6):1937-49. doi: 10.1097/CCM.0b013e31817603ba PMID: 18496365
12. Salluh JI, Verdeal JC, Mello GW, Araujo LV, Martins GA, de Sousa Santino M, et al. Cortisol levels in patients with severe community-acquired pneumonia. Intensive Care Med. 2006; 32(4):595-8. doi: 10.1007/s00134-005-0046-9 PMID: 16552616
13. Salluh JI, Bozza FA, Soares M, Verdeal JC, Castro-Faria-Neto HC, Lapa ESJR, et al. Adrenal response in severe community-acquired pneumonia: impact on outcomes and disease severity. Chest. 2008; 134 (5):947-54. doi: 10.1378/chest.08-1382 PMID: 18753464
14. Tagami T, Matsui H, Horiguchi H, Fushimi K, Yasunaga H. Low-dose corticosteroid use and mortality in severe community-acquired pneumonia patients. The European respiratory journal. 2015; 45(2):463-72. doi: 10.1183/09031936.00081514 PMID: 25323232
15. Wagner HN Jr., Bennett IL Jr., Lasagna L, Cluff LE, Rosenthal MB, Mirick GS. The effect of hydrocortisone upon the course of pneumococcal pneumonia treated with penicillin. Bull Johns Hopkins Hosp. 1956; 98(3):197-215. PMID: 13304518
16. McHardy VU, Schonell ME. Ampicillin dosage and use of prednisolone in treatment of pneumonia: cooperative controlled trial. Br Med J. 1972; 4(5840):569-73. PMID: 4404939
17. Marik P, Kraus P, Sribante J, Havlik I, Lipman J, Johnson DW. Hydrocortisone and tumor necrosis factor in severe community-acquired pneumonia. A randomized controlled study. Chest. 1993; 104 (2):389-92. PMID: 8339624
18. Confalonieri M, Urbino R, Potena A, Piattella M, Parigi P, Puccio G, et al. Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study. Am J Respir Crit Care Med. 2005; 171(3):242-8. doi: 10.1164/rccm.200406-808OC PMID: 15557131
19. El-Ghamrawy AH, Shokeir MH, Esmat AA. Effects of low-dose hydrocortisone in ICU patients with severe community-acquired pneumonia. Egyptian Journal of Chest. 2006; 55:91-9.
20. Mikami K, Suzuki M, Kitagawa H, Kawakami M, Hirota N, Yamaguchi H, et al. Efficacy of corticosteroids in the treatment of community-acquired pneumonia requiring hospitalization. Lung. 2007; 185(5):249-55. doi: 10.1007/s00408-007-9020-3 PMID: 17710485
21. Snijders D, Daniels JM, de Graaff CS, van der Werf TS, Boersma WG. Efficacy of corticosteroids in community-acquired pneumonia: a randomized double-blinded clinical trial. Am J Respir Crit Care Med. 2010; 181(9):975-82. doi: 10.1164/rccm.200905-0808OC PMID: 20133929
22. Fernandez-Serrano S, Dorca J, Garcia-Vidal C, Fernandez-Sabe N, Carratala J, Fernandez-Aguera A, et al. Effect of corticosteroids on the clinical course of community-acquired pneumonia: a randomized controlled trial. Crit Care. 2011; 15(2):R96. doi: 10.1186/cc10103 PMID: 21406101
23. Meijvis SC, Hardeman H, Remmelts HH, Heijligenberg R, Rijkers GT, van Velzen-Blad H, et al. Dexamethasone and length of hospital stay in patients with community-acquired pneumonia: a randomised, double-blind, placebo-controlled trial. Lancet. 2011; 377(9782):2023-30. doi: 10.1016/S0140-6736(11)60607-7 PMID: 21636122
24. Sabry NA, Omar EE. Corticosteroids and ICU course of community acquired pneumonia in Egyptian settings. Pharmacol Pharm. 2011; 2:73-81.
25. Remmelts HH, Meijvis SC, Heijligenberg R, Rijkers GT, Oosterheert JJ, Bos WJ, et al. Biomarkers define the clinical response to dexamethasone in community-acquired pneumonia. J Infect. 2012; 65 (1):25-31. doi: 10.1016/j.jinf.2012.03.008 PMID: 22410382
26. Nafae RM, Ragab MI, Amany FM, Rashed SB. Adjuvant role of corticosteroids in the treatment of community-acquired pneumonia. Egyptian Journal of Chest Diseases and Tuberculosis. 2013; 62:439-45.
27. Blum CA, Nigro N, Briel M, Schuetz P, Ullmer E, Suter-Widmer I, et al. Adjunct prednisone therapy for patients with community-acquired pneumonia: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2015; 385(9977):1511-8. doi: 10.1016/S0140-6736(14)62447-8 PMID: 25608756
28. Torres A, Sibila O, Ferrer M, Polverino E, Menendez R, Mensa J, et al. Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: a randomized clinical trial. Jama. 2015; 313(7):677-86. doi: 10.1001/jama.2015.88 PMID: 25688779
29. Siempos II, Vardakas KZ, Kopterides P, Falagas ME. Adjunctive therapies for community-acquired pneumonia: a systematic review. J Antimicrob Chemother. 2008; 62(4):661-8. doi: 10.1093/jac/dkn283 PMID: 18641037
30. Salluh JI, Shinotsuka CR, Soares M, Bozza FA, Lapa e Silva JR, Tura BR, et al. Cortisol levels and adrenal response in severe community-acquired pneumonia: a systematic review of the literature. J Crit Care. 2010; 25(3):541.e1-8.
31. Chen Y, Li K, Pu H, Wu T. Corticosteroids for pneumonia. Cochrane Database Syst Rev. 2011(3): Cd007720. doi: 10.1002/14651858.CD007720.pub2 PMID: 21412908
32. Nie W, Zhang Y, Cheng J, Xiu Q. Corticosteroids in the treatment of community-acquired pneumonia in adults: a meta-analysis. PLoS One. 2012; 7(10):e47926. doi: 10.1371/journal.pone.0047926 PMID: 23112872
33. Shafiq M, Mansoor MS, Khan AA, Sohail MR, Murad MH. Adjuvant steroid therapy in communityacquired pneumonia: a systematic review and meta-analysis. J Hosp Med. 2013; 8(2):68-75. doi: 10. 1002/jhm.1992 PMID: 23184813
34. Gusmao-Flores D. Corticosteroid therapy for severe community-acquired pneumonia: a meta-analysis. Respir Care. 2014; 59(8):e118.
35. Horita N, Otsuka T, Haranaga S, Namkoong H, Miki M, Miyashita N, et al. Adjunctive Systemic Corticosteroids for Hospitalized Community-Acquired Pneumonia: Systematic Review and Meta-Analysis 2015 Update. Sci Rep. 2015; 5:14061. doi: 10.1038/srep14061 PMID: 26374694
36. Siemieniuk RA, Meade MO, Alonso-Coello P, Briel M, Evaniew N, Prasad M, et al. Corticosteroid Therapy for Patients Hospitalized With Community-Acquired Pneumonia: A Systematic Review and Metaanalysis. Ann Intern Med. 2015; 163(7):519-28. doi: 10.7326/M15-0715 PMID: 26258555
37. Wan YD, Sun TW, Liu ZQ, Zhang SG, Wang LX, Kan QC. Efficacy and Safety of Corticosteroids for Community-Acquired Pneumonia: A Systematic Review and Meta-Analysis. Chest. 2016; 149(1):209-19. doi: 10.1378/chest.15-1733 PMID: 26501852
38. Lim WS, van der Eerden MM, Laing R, Boersma WG, Karalus N, Town GI, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 2003; 58(5):377-82. doi: 10.1136/thorax.58.5.377 PMID: 12728155
39. Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997; 336(4):243-50. doi: 10. 1056/NEJM199701233360402 PMID: 8995086
40. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007; 44 Suppl 2:S27-72.
41. BTS Guidelines for the Management of Community Acquired Pneumonia in Adults. Thorax. 2001; 56 Suppl 4:Iv1-64.
42. Marti C, Garin N, Grosgurin O, Poncet A, Combescure C, Carballo S, et al. Prediction of severe community-acquired pneumonia: a systematic review and meta-analysis. Crit Care. 2012; 16(4):R141. doi: 10. 1186/cc11447 PMID: 22839689
43. Charles PG, Wolfe R, Whitby M, Fine MJ, Fuller AJ, Stirling R, et al. SMART-COP: a tool for predicting the need for intensive respiratory or vasopressor support in community-acquired pneumonia. Clin Infect Dis. 2008; 47(3):375-84. doi: 10.1086/589754 PMID: 18558884
44. Rello J, Rodriguez A, Lisboa T, Gallego M, Lujan M, Wunderink R. PIRO score for community-acquired pneumonia: a new prediction rule for assessment of severity in intensive care unit patients with community-acquired pneumonia. Crit Care Med. 2009; 37(2):456-62. doi: 10.1097/CCM.0b013e318194b021 PMID: 19114916
45. Sligl WI, Marrie TJ. Severe community-acquired pneumonia. Crit Care Clin. 2013; 29(3):563-601. doi: 10.1016/j.ccc.2013.03.009 PMID: 23830654
46. Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol. 2005; 5:13. doi: 10.1186/1471-2288-5-13 PMID: 15840177
47. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. Bmj. 2003; 327(7414):557-60. doi: 10.1136/bmj.327.7414.557 PMID: 12958120
48. Sterne JA, Egger M, Smith GD. Systematic reviews in health care: Investigating and dealing with publication and other biases in meta-analysis. Bmj. 2001; 323(7304):101-5. PMID: 11451790
49. Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. Bmj. 2011; 343:d5928. doi: 10.1136/bmj.d5928 PMID: 22008217
50. Fernandez-Botran R, Uriarte SM, Arnold FW, Rodriguez-Hernandez L, Rane MJ, Peyrani P, et al. Contrasting inflammatory responses in severe and non-severe community-acquired pneumonia. Inflammation. 2014; 37(4):1158-66. doi: 10.1007/s10753-014-9840-2 PMID: 24557760
51. Galon J, Franchimont D, Hiroi N, Frey G, Boettner A, Ehrhart-Bornstein M, et al. Gene profiling reveals unknown enhancing and suppressive actions of glucocorticoids on immune cells. Faseb j. 2002; 16 (1):61-71. doi: 10.1096/fj.01-0245com PMID: 11772937
52. Sibila O, Luna CM, Agusti C, Baquero S, Gando S, Patron JR, et al. Effects of glucocorticoids in ventilated piglets with severe pneumonia. The European respiratory journal. 2008; 32(4):1037-46. doi: 10. 1183/09031936.00009208 PMID: 18508831
53. Lamontagne F, Briel M, Guyatt GH, Cook DJ, Bhatnagar N, Meade M. Corticosteroid therapy for acute lung injury, acute respiratory distress syndrome, and severe pneumonia: a meta-analysis of randomized controlled trials. J Crit Care. 2010; 25(3):420-35. doi: 10.1016/j.jcrc.2009.08.009 PMID: 19896324
54. Carratala J, Garcia-Vidal C, Ortega L, Fernandez-Sabe N, Clemente M, Albero G, et al. Effect of a 3-step critical pathway to reduce duration of intravenous antibiotic therapy and length of stay in community-acquired pneumonia: a randomized controlled trial. Arch Intern Med. 2012; 172(12):922-8. doi: 10. 1001/archinternmed.2012.1690 PMID: 22732747
55. Annane D, Bellissant E, Bollaert PE, Briegel J, Confalonieri M, De Gaudio R, et al. Corticosteroids in the treatment of severe sepsis and septic shock in adults: a systematic review. Jama. 2009; 301(22):2362-75. doi: 10.1001/jama.2009.815 PMID: 19509383